Back

Acvr1b loss promotes formation of precancerous lesions from acinar and ductal cells of origin

Saeki, K.; Patil, S.; Sun, Y.; Su, G. H.; Kopp, J. L.

2023-06-08 cancer biology
10.1101/2023.06.08.544226 bioRxiv
Show abstract

Background & AimsPancreatic ductal adenocarcinoma (PDAC) can develop from precursor lesions, including pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN). Previous studies indicated that loss of Acvr1b accelerates the Kras-mediated development of papillary IPMN in the mouse pancreas, however, the cell type predominantly affected by these genetic changes remains unclear. MethodsWe investigated the contribution of cellular origin by inducing IPMN associated mutations-KRASG12D expression and Acvr1b loss - specifically in acinar (Ptf1aCreER;KrasLSL-G12D;Acvr1bfl/flmice) or ductal (Sox9CreER;KrasLSL- G12D;Acvr1bfl/flmice) cells in mice. We then performed MRI imaging and a thorough histopathological analysis of their pancreatic tissues. ResultsThe loss of Acvr1b increased the development of PanIN and IPMN-like lesions when either acinar and ductal cells expressed a Kras mutation. MRI, immunohistochemistry and histology revealed large IPMN-like lesions in these mice that exhibited features of flat, gastric epithelium. In addition, cyst formation in both mouse models was accompanied by chronic pancreatitis. Experimental acute pancreatitis accelerated the development of large mucinous cysts and PanIN when acinar, but not ductal, cells expressed mutant Kras and lost Acvr1b. ConclusionThese findings indicate that loss of Acvr1b in the presence of the Kras oncogene promotes the development of large and small precancerous lesions from both ductal and acinar cells. However, the IPMN-like phenotype was not equivalent to that observed when these mutations were made in all pancreatic cells during development. Our study underscores the significance of the cellular context in the initiation and progression of precursor lesions from exocrine cells.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Cellular and Molecular Gastroenterology and Hepatology
46 papers in training set
Top 0.1%
18.3%
2
Gut
40 papers in training set
Top 0.1%
11.8%
3
Gastro Hep Advances
11 papers in training set
Top 0.1%
10.5%
4
The American Journal of Pathology
32 papers in training set
Top 0.1%
6.7%
5
Gastroenterology
42 papers in training set
Top 0.1%
6.7%
50% of probability mass above
6
eLife
5828 papers in training set
Top 30%
4.0%
7
Cell Death & Disease
126 papers in training set
Top 0.6%
4.0%
8
The Journal of Pathology
26 papers in training set
Top 0.2%
3.4%
9
Disease Models & Mechanisms
119 papers in training set
Top 0.6%
3.2%
10
JCI Insight
277 papers in training set
Top 2%
3.1%
11
PLOS ONE
5266 papers in training set
Top 49%
1.7%
12
Nature Communications
5641 papers in training set
Top 45%
1.7%
13
Molecular Cancer Research
49 papers in training set
Top 0.7%
1.7%
14
Scientific Reports
3612 papers in training set
Top 59%
1.5%
15
Hepatology
22 papers in training set
Top 0.3%
1.4%
16
Cell Reports
1498 papers in training set
Top 21%
1.4%
17
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 33%
1.3%
18
Cell Death & Differentiation
48 papers in training set
Top 0.9%
1.0%
19
The FASEB Journal
194 papers in training set
Top 6%
0.8%
20
Cancer Research
130 papers in training set
Top 3%
0.8%
21
Frontiers in Genetics
230 papers in training set
Top 7%
0.6%
22
Journal of Clinical Investigation
179 papers in training set
Top 6%
0.6%
23
Cell Metabolism
57 papers in training set
Top 2%
0.6%
24
Development
497 papers in training set
Top 5%
0.6%
25
Oncogene
85 papers in training set
Top 2%
0.6%